8-K: Hims & Hers Health Inc. Reports Strong Q3 2024 Results, Raises Full-Year Guidance

Hims & Hers Health, Inc. announced a 77% year-over-year revenue increase to $401.6 million, alongside a net income of $75.6 million and raised its full-year revenue and adjusted EBITDA guidance.

Summary

• Hims & Hers Health, Inc. reported a significant 77% year-over-year increase in revenue for the third quarter of 2024, reaching $401.6 million.
• The company achieved a net income of $75.6 million in Q3 2024, a substantial improvement from a net loss of $7.6 million in the same quarter of the previous year.
• Adjusted EBITDA for Q3 2024 was $51.1 million, compared to $12.3 million in Q3 2023.
• The number of subscribers grew to 2.0 million, a 44% increase year-over-year.
• The company has raised its full-year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion.
• Full-year 2024 Adjusted EBITDA guidance has been raised to a range of $173 million to $178 million.
• More than 1 million subscribers are now utilizing a personalized solution on the platform, representing over half of the subscriber base.
• The company's new weight loss offering is contributing to the strong growth trajectory.
• Subscriber growth, excluding contributions from GLP-1 solutions, increased by 40% year-over-year.
• Monthly online revenue per average subscriber increased by 24% year-over-year to $67.
• The average order value (AOV) increased by 48% year-over-year to $147.
• Net cash provided by operating activities was $85.3 million for the third quarter of 2024.
• Free cash flow was $79.4 million for the third quarter of 2024.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong financial results, significant growth metrics, and raised guidance. The company's focus on innovation and personalized care also contributes to the positive outlook.

Positives

• The company experienced substantial revenue growth, indicating strong market demand for its services.
• Hims & Hers achieved profitability with a significant net income, demonstrating improved financial health.
• The company's adjusted EBITDA saw a large increase, reflecting operational efficiency and cost management.
• The subscriber base grew significantly, showing increased customer adoption of the platform.
• The company raised its full-year guidance, indicating confidence in future performance.
• Personalized solutions are gaining traction, with over half of the subscriber base now utilizing them.
• The company is seeing strong growth in its weight loss offerings, which is a new and growing market.
• The company is seeing strong cash flow from operations and free cash flow.
• The company has a strong balance sheet with over $254 million in cash, cash equivalents, and short-term investments and no debt.
• The company has a share repurchase program in place to capitalize on market opportunities.

Negatives

• Gross margin decreased to 79% in Q3 2024 from 83% in Q3 2023, primarily due to higher costs related to the new weight loss offerings.
• The company is experiencing shortages of name-brand GLP-1 medications, which is impacting some customers.

Risks

• The company's future performance is subject to various risks and uncertainties, including regulatory changes and market conditions.
• The company's ability to maintain its growth trajectory depends on its ability to innovate and expand its offerings.
• The company faces competition from other healthcare providers and platforms.
• The company's reliance on third-party suppliers and partners could pose risks to its operations.
• The company's ability to comply with complex and evolving legal and regulatory requirements is critical to its success.
• The company is subject to risks related to data privacy and security.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects full-year 2024 revenue to be between $1.460 billion and $1.465 billion and Adjusted EBITDA to be between $173 million and $178 million. The company also anticipates that 2024 will mark its first full year of net income profitability. The company is aiming for a long-term Adjusted EBITDA margin target of at least 20% before 2030.

Management Comments

• Andrew Dudum, co-founder and CEO, stated that the company's execution against its strategy is allowing it to reach millions of individuals across the country.
• Yemi Okupe, CFO, stated that the company's model is rapidly gaining scale, driving accelerating top line growth, improving profitability and strong cash flow.
• Andrew Dudum, CEO and Co-Founder, stated that the company is on a clear path to achieving its long-term Adjusted EBITDA margin target of at least 20% before 2030.

Industry Context

The company's strong performance reflects the growing trend of telehealth and the increasing demand for convenient and affordable healthcare solutions. The company is leveraging technology to provide personalized care, which is a key differentiator in the market. The company's focus on weight loss is also aligned with the growing awareness of the obesity epidemic and the need for effective treatments.

Comparison to Industry Standards

• Hims & Hers' 77% year-over-year revenue growth significantly outpaces the average growth rate of many traditional healthcare providers and even some other telehealth companies.
• The company's adjusted EBITDA growth of 317% year-over-year is also exceptional, indicating strong operational efficiency and cost management compared to industry averages.
• The subscriber growth of 44% year-over-year demonstrates a strong customer acquisition rate, which is a key metric for subscription-based businesses.
• The company's focus on personalized solutions and its technology platform are differentiating factors compared to other telehealth providers that may offer more generic services.
• The company's expansion into weight loss with compounded GLP-1 medications is a strategic move to capitalize on a growing market, which is not a focus for all telehealth companies.
• The company's gross margin of 79% is relatively high for the healthcare industry, but the decrease from 83% in the previous year indicates some cost pressures, particularly in the weight loss segment.
• The company's free cash flow of $79.4 million in Q3 2024 is a strong indicator of financial health and the ability to reinvest in the business.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and increased profitability.
• Employees will benefit from the company's growth and success.
• Customers will benefit from the company's focus on personalized care and affordable solutions.
• Suppliers and partners will benefit from the company's increased scale and demand for its services.
• Creditors will benefit from the company's strong financial health and cash flow.

Next Steps

• The company plans to continue evolving personalized solutions in each of its specialties.
• The company will remain focused on driving increased access to high-quality care, supported by operational efficiencies.
• The company plans to continue leveraging its technology assets to help more individuals achieve better health outcomes.
• The company will continue to invest in its infrastructure and platform capabilities.

Key Dates

Keywords

telehealth, digital health, subscription, personalized medicine, weight loss, GLP-1, EBITDA, revenue, healthcare, pharmacy